Latest Ras subfamily Stories
Study May Lead to More Targeted Treatments for Cancers and "Rasopathies" CINCINNATI, Nov.
Focus on research and development for small molecule inhibitors of oncogenic K-Ras - the most commonly mutated oncogene in human cancers BOSTON and TOKYO, Nov.
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice.
Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and
A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.
Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity
Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014
ACA is Changing How Some Businesses Can Use HRAs in 2014 Park City, Utah (PRWEB) January 21, 2014 Today, Zane Benefits, the #1 Online Health Benefits
In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.
- A hairdresser.